Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 21, 2014; 20(35): 12473-12484
Published online Sep 21, 2014. doi: 10.3748/wjg.v20.i35.12473
Resection of hepatitis B virus-related hepatocellular carcinoma: Evolving strategies and emerging therapies to improve outcome
Gar-Yang Chau
Gar-Yang Chau, Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, and School of Medicine, National Yang-Ming University, Taipei 112, Taiwan
Author contributions: Chau GY designed the paper, analyzed the data and wrote the paper.
Supported by Grants from the Taipei Veterans General Hospital, No. V100C-142; and Center of Excellence for Cancer Research at TVGH, No. DOH100-TD-C-111-007
Correspondence to: Gar-Yang Chau, MD, MPH, Professor of Surgery, Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, and School of Medicine, National Yang-Ming University, Shih-pai, Taipei 112, Taiwan. gychau@vghtpe.gov.tw
Telephone: +886-2-28757652 Fax: +886-2-28757537
Received: December 15, 2013
Revised: January 28, 2014
Accepted: April 1, 2014
Published online: September 21, 2014
Core Tip

Core tip: Chronic hepatitis B virus infection is the main cause of hepatocellular carcinoma (HCC). Liver resection is currently the mainstay of treatment. However, the postresectional tumor recurrence rates remain high. There is an ever-increasing demand on surgeons to perform curative liver resection in HCC, with the hope of avoiding tumor recurrences. The author presents a review of the recently evolving strategies and emerging therapies to improve patient outcomes, including a policy of accurate preoperative staging, adequate resection, intensive postoperative follow-up, and early initiation of effective adjuvant therapy, with particular reference to the current status of adjuvant therapies in HCC patients after liver resection.